OverviewChartNewsTraderScreen

ALMIRALL S.A. EO -,12/  ES0157097017  /

Lang & Schwarz
16/05/2024  22:22:46 Chg. +0.050 Volume Bid- Ask- High Low
9.370EUR +0.54% -
Turnover: -		 -Bid Size: - -Ask Size: - 9.475 9.275
GlobeNewswire 16/04 Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
GlobeNewswire 13/03 Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermat...
GlobeNewswire 05/03 Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of...
GlobeNewswire 10/01 Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
GlobeNewswire 14/11/2023 Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
GlobeNewswire 14/11/2023 Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for de...
GlobeNewswire 05/10/2023 Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
GlobeNewswire 21/09/2023 Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
GlobeNewswire 18/09/2023 Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and No...
GlobeNewswire 12/09/2023 Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockh...
GlobeNewswire 07/09/2023 Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR...
GlobeNewswire 25/03/2022 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corpo...
GlobeNewswire 16/03/2022 Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
GlobeNewswire 15/03/2022 ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
GlobeNewswire 14/03/2022 Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
GlobeNewswire 08/03/2022 Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NU...
GlobeNewswire 02/03/2022 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, ...
GlobeNewswire 01/03/2022 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 01/02/2022 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 03/01/2022 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 16/12/2021 China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment o...
GlobeNewswire 01/12/2021 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 10/11/2021 Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
GlobeNewswire 08/11/2021 Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
GlobeNewswire 04/11/2021 Athenex Provides Third Quarter 2021 Corporate and Financial Update